Mobile

A PHASE Ib/II, OPEN LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OTHER...

Update Il y a 4 ans
Reference: EUCTR2006-005552-33

A PHASE Ib/II, OPEN LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OTHER LOW-GRADE, CD20, B CELL NON HODGKIN’S LYMPHOMAS THAT HAVE PROGRESSED FOLLOWING PREVIOUS RITUXIMAB THERAPY

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

phase II: to evaluate the safety of multiple doses of Apo2L/TRAIL administered in combination with rituximab to subjects with relapsed follicular NHL who have progressed following stable disease or an objective response to a previous rituximab-containing regimen, and to evaluate the efficacy of multiple doses of Apo2L/TRAIL administered in combination with rituximab to subjects with relapsed follicular NHL, as measured by response rate.

Inclusion criteria

  • phase II: patients with follicular NHL

Links